Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?
Open Access
- 14 January 2022
- journal article
- research article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 31, 100518
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Targeted Therapies for Ovarian CancerBest Practice & Research Clinical Obstetrics & Gynaecology, 2017
- Young Israeli women with epithelial ovarian cancer: prevalence ofBRCAmutations and clinical correlatesJournal of Gynecologic Oncology, 2017
- Comparison of ECOG/WHO Performance Status and ASA Score as a Measure of Functional StatusJournal of Pain and Symptom Management, 2015
- Development and Assessment of Memorial Sloan Kettering Cancer Center’s Surgical Secondary Events Grading SystemAnnals of Surgical Oncology, 2014
- Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control studyJournal of Surgical Oncology, 2014
- Staging classification for cancer of the ovary, fallopian tube, and peritoneumInternational Journal of Gynecology & Obstetrics, 2013
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian CancerJAMA, 2012
- Hydraulic Fracturing To Improve ProductionThe Way Ahead, 2010
- A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot StudyAnnals of Surgical Oncology, 2006
- Reduction of cellular cisplatin resistance by hyperthermia—a reviewInternational Journal of Hyperthermia, 1997